Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Launched the National Campaign for the Prevention of Cardiovascular Diseases: No.1 Cause of Hasbani Launched the National Campaign for the Prevention of Cardiovascular Diseases: No.1 Cause of Death in Lebanon

 
The Ministry of Public Health launched in collaboration with the national committee for the prevention of cardiovascular diseases and Yaduna -Women Heart Health Center the National campaign for the early detection and prevention of cardiovascular diseases under the title “Don’t wait, your heart can’t wait”, during a conference held under the patronage and in the presence of Deputy Prime Minister Health Minister Ghassan Hasbani at the Adnan Kassar Edifice in Bir Hassan.
 
The Head of Primary health care Department at Health Ministry Dr. Randa Hamadeh made a presentation of the path of the national campaign. “This campaign that starts today will last for three months until the end of April. It will kick off from the national network of primary health care centers located across all the Lebanese territory and aims at providing services to citizens, i.e. free cardiovascular examinations for men and women,”Dr. Hamadeh added.
 
The Chairperson of Yaduna foundation Wafaa Sleiman delivered a statement in which she noted that the increasing number of women who underwent an early testing at the Women Heart Health Center, and the detection of many cases of cardiovascular diseases contributed greatly in the treatment of these cases, and led us to activate the prevention and awareness actions across all the Lebanese territory.
 
Hasbani

In a statement, Hasbani noted that the non-communicable diseases cause the death of 38 million people each year, 28 million death cases of which occur in low- and middle-income countries.

“Non-communicable diseases threaten the progress towards achieving the Millennium Development Goals. Poverty and such diseases are highly correlated and it is expected that the rapid growth of these diseases hinder poverty alleviation initiatives in low-income countries, in particular by increasing household costs associated with healthcare services,” Hasbani added.
 
Hasbani highlighted that this activity complements all these efforts, especially that it is integrated with that of Yaduna - Women Heart Health Center, knowing that the primary healthcare brings together all sectors to provide best services to citizens.(Read more...)
    ...
    20
    ...
ATC Name B/G Ingredients Dosage Form Price
R03AC18 ONBREZ BREEZHALER B Indacaterol maleate - 150mcg 150mcg Capsule, inhalation 2,284,532 L.L
R03AK06 FLUDALT DUO G Salmeterol (xinafoate) - 50mcg, Fluticasone propionate - 100mcg Capsule, inhalation 1,777,706 L.L
R03AK06 FLUDALT DUO G Salmeterol (xinafoate) - 50mcg, Fluticasone propionate - 250mcg Capsule, inhalation 2,487,891 L.L
R03AK06 FLUDALT DUO G Salmeterol (xinafoate) - 50mcg, Fluticasone propionate - 500mcg Capsule, inhalation 3,169,668 L.L
R03AK12 ZEPHIRUS B Salmeterol - 20mcg, Budesonide - 120mcg Capsule, inhalation 1,412,378 L.L
R03AK12 ZEPHIRUS B Salmeterol - 20mcg, Budesonide - 240mcg Capsule, inhalation 1,678,459 L.L
R03AL04 ULTIBRO BREEZHALER B Indacaterol - 110mcg, Glycopyronium - 50mcg Capsule, inhalation 4,031,528 L.L
R03BA02 AERONIDE G Budesonide - 200mcg 200mcg Capsule, inhalation 1,150,329 L.L
R03BA02 AERONIDE G Budesonide - 400mcg 400mcg Capsule, inhalation 2,116,552 L.L
R03BB04 SPIRIVA WITH HANDIHALER B Tiotropium bromide - 18mcg 18mcg Capsule, inhalation 3,179,531 L.L
R03BB04 NEUMOTROPIO G Tiotropium bromide - 10mcg 10mcg Capsule, inhalation 3,115,844 L.L
R03BB06 SEEBRI BREEZHALER B Glycopyronium Bromide - 50mcg 50mcg Capsule, inhalation 2,687,685 L.L
A03AX13 OVOL FOR GAZ B Simethicone - 180mg 180mg Capsule, liquid gel 241,892 L.L
C10AB05 FENOGAL G Fenofibrate micronised - 200mg 200mg Capsule, micronized 392,402 L.L
G04CA02 PROSTAFINE G Tamsulosin HCl - 0.4mg 0.4mg Capsule, modified release 761,511 L.L
G04CA02 TALUSIN G Tamsulosin HCl - 0.4mg 0.4mg Capsule, modified release 683,440 L.L
C08DA51 TARKA B Verapamil - 180mg, Trandolapril - 2mg Capsule, modified release 2,422,948 L.L
G04BD06 MICTONORM XL B Propiverine HCl - 30mg 30mg Capsule, modified release 1,648,895 L.L
G04BD06 MICTONORM XL B Propiverine HCl - 45mg 45mg Capsule, modified release 1,877,348 L.L
N06AX16 DEPREVIX HELLAS G Venlafaxine - 75mg 75mg Capsule, prolonged release 564,414 L.L
N06AX16 DEPREVIX HELLAS G Venlafaxine - 75mg 75mg Capsule, prolonged release 564,414 L.L
N06AX16 VENLAFAXINE BIOGARAN LP G Venlafaxine HCl - 75mg 75mg Capsule, prolonged release 584,571 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 1mg 1mg Capsule, prolonged release L.L
N06AX16 DEPREVIX HELLAS G Venlafaxine - 150mg 150mg Capsule, prolonged release 968,910 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 3mg 3mg Capsule, prolonged release L.L
N06AX16 DEPREVIX HELLAS G Venlafaxine - 150mg 150mg Capsule, prolonged release 968,910 L.L
N06AX16 VENLAFAXINE BIOGARAN LP G Venlafaxine HCl - 37.5mg 37.5mg Capsule, prolonged release 538,881 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 3mg 3mg Capsule, prolonged release 68,645,618 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 1mg 1mg Capsule, prolonged release 25,729,044 L.L
L04AD02 ADVAGRAF B Tacrolimus monohydrate - 5mg 5mg Capsule, prolonged release 85,485,667 L.L
    ...
    20
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025